Related Experiment Video
Updated: Jun 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Comment on article "Enoxaparin dose associated with decreased risk of death in COVID-19"]
Mateo Porres-Aguilar1, Javier E Anaya-Ayala2
1Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, Divisions of Hospital and Adult Thrombosis Medicine, Department of Internal Medicine. El Paso, Texas, United States of America.
Insights
This letter discusses thromboprophylactic strategies and the use of heparins for managing COVID-19. It examines enoxaparin
Area of Science:
- Critical Care Medicine
- Hematology
- Infectious Diseases
Background:
- The article
- Enoxaparin dose associated with decreased risk of death in COVID-19
- prompted a discussion on thromboprophylaxis in COVID-19 patients.
- Current thromboprophylactic strategies are being re-evaluated in light of the pandemic.
Discussion:
- The role of heparin, specifically enoxaparin, in managing COVID-19 associated coagulopathy is explored.
- The potential benefits of adjusted enoxaparin dosing for reducing mortality in COVID-19 patients are considered.
Key Insights:
- Heparins may play a significant role in the clinical management of COVID-19.
- Evidence suggests a potential link between enoxaparin dosage and reduced mortality risk in COVID-19.
Outlook:
- Further research is warranted to establish optimal heparin protocols for COVID-19 treatment.
- The findings may influence future guidelines for anticoagulant therapy in viral infections.
Abstract:
In this letter to the editor, apropos of the article "Enoxaparin dose associated with decreased risk of death in COVID-19", it is discussed the role of the current thromboprophylactic strategies, as well as the potential role of heparins in the management of COVID-19.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism III: Nursing Management

